PlexBio Co., Ltd. innovates and produces advanced in vitro diagnostic solutions for applications in molecular biology and immunology. The company furnishes comprehensive workflow guidance; automated extraction systems for sample preparation; the IntelliPlex platform, engineered around its proprietary πCode™ technology for high-throughput, sample-to-result multiplexing assays; specialized oncology panels for detecting lung cancer, various mutations, and gene rearrangements; IntelliPlex test kits for SARS-CoV-2 and influenza, alongside variant analysis kits for SARS-CoV-2; and essential πCode™ coupling reagents. Recently, PlexBio has broadened its strategic alliances, including a significant partnership with Japan's Denka Group to co-develop automated infectious disease diagnostic platforms and expand its Contract Development and Manufacturing Organization (CDMO) services. The company also obtained FDA Certification for its IntelliPrep TRIO System, enabling market expansion into Korea. Established in 2009, PlexBio Co., Ltd. maintains its headquarters in Taipei, Taiwan.